EU/3/19/2202

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2202 was granted by the European Commission to Clinical Network Services (NL) B.V., Netherlands, for (16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid (also known as zotiraciclib) for the treatment of glioma.

In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.

Key facts

Active substance
(16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid
Disease / condition
Treatment of glioma
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2202

Sponsor's contact details

Scendea (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: orphan@scendea.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating